Skip to main content
Spexis AG logo

Spexis AG — Investor Relations & Filings

Ticker · SPEX ISIN · CH0106213793 LEI · 391200S8HJE1I96FIG04 SW Manufacturing
Open in API
Filings indexed 194 across all filing types
Latest filing 2022-12-13 Regulatory Filings
Country CH Switzerland
Listing SW SPEX

About Spexis AG

https://www.polyphor.com/

Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Spexis gibt vielversprechende präklinische Daten für Balixafortide in Kombination mit bereits erhältlichen Therapien zur Behandlung von B-Zell-Lymphomen bekannt
Regulatory Filings Classification · 95% confidence The document is a press release dated 13.12.2022 from Spexis AG announcing 'vielversprechende präklinische Daten' (promising preclinical data) for their drug candidate Balixafortide. It details research findings, quotes management and researchers, and mentions that detailed results will be submitted for presentation at an upcoming medical conference. This format—a news announcement about research progress, often released outside of standard SEC filings like 10-K or ER—fits best under a general regulatory announcement or news release category. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal presentation (IP), and it is a specific announcement of research findings, it is best classified as a general Regulatory Filing (RNS) as it serves as a broad regulatory disclosure to the market about material non-public information, or potentially a Research Update/Announcement, which aligns closest with the 'RNS' fallback category among the provided options for non-standard corporate news.
2022-12-13 German
Spexis to present at BIO-Europe 2022
Regulatory Filings Classification · 100% confidence The document is a short press release dated October 18, 2022, announcing that Spexis AG will present at the BIO-Europe® 2022 conference in late October/early November 2022. It details the CEO's presentation time and mentions one-on-one meetings. This is not a formal financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ). It is an announcement about future corporate activity, specifically participation in an industry conference. This type of announcement, which is essentially corporate news that doesn't fit the highly specific financial/regulatory categories, is best classified as a general Regulatory Filing (RNS) or potentially a general announcement, but given the options, RNS serves as the best general regulatory/corporate news fallback when specific categories like ER or DIV do not apply. Since it is a news announcement about corporate events, RNS is the most appropriate general classification.
2022-10-18 English
Spexis to present at BIO-Europe® 2022
Report Publication Announcement Classification · 99% confidence The document is a press release dated October 18, 2022, announcing that Spexis AG will present at the BIO-Europe® 2022 conference. It details the CEO's presentation schedule and availability for one-on-one meetings. This type of announcement, which informs the public about participation in an industry event (like a conference presentation or investor meeting schedule), does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate update related to investor relations and business development activities. Since it is not a transcript (CT) or a formal presentation document (IP), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it is a standard news release format.
2022-10-18 English
Spexis announces positive renal impairment clinical trial results with balixafortide
Regulatory Filings Classification · 99% confidence The document is titled 'News Details' and begins with 'Ad-hoc | 22 September 2022 07:15'. It explicitly states 'Release of an ad hoc announcement pursuant to Art. 53 LR'. Ad-hoc announcements are typically used for material, non-public information that must be disclosed immediately. This content details positive clinical trial results for a drug (balixafortide), which is significant corporate news. Since it is not a full Annual Report (10-K), a comprehensive Interim Report (IR), an Earnings Release (ER) focusing on financial figures, or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate general category for immediate, material, non-standard regulatory news that doesn't fit other specific categories is the general Regulatory Filings fallback category (RNS). It is an announcement of study results, not a formal financial report or presentation.
2022-09-22 English
Spexis announces positive renal impairment clinical trial results with balixafortide
Regulatory Filings Classification · 98% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and announces positive clinical trial results for a drug candidate (balixafortide). It provides key findings, context about the drug, and contact information. This format—a brief, timely announcement of material, non-public information released outside of standard periodic filings—is characteristic of a general regulatory disclosure or press release. Since it is not a full Annual Report (10-K), a Quarterly Report (IR), an Earnings Release (ER), or a specific shareholder/director transaction, the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings), as it serves as a catch-all for such ad hoc disclosures not covered by more specific codes.
2022-09-22 English
Spexis mit positiven Ergebnissen für Balixafortide bei Niereninsuffizienz
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and is dated 22.09.2022. It announces positive study results for the drug Balixafortide regarding kidney insufficiency. This format—a brief, timely announcement of material, non-public information (like clinical trial results) released via an official channel (indicated by 'EQS News-Service' and 'Ad hoc-Mitteilung')—is characteristic of a general regulatory disclosure or press release that doesn't fit a specific financial report category like 10-K or IR. Since it is a specific, material announcement that is not a formal financial report, dividend notice, or management change, the most appropriate general regulatory category is 'Regulatory Filings' (RNS), which serves as a fallback for such official, non-standardized disclosures, especially those originating from non-US exchanges or specific regulatory requirements not covered by the primary SEC forms.
2022-09-22 German

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.